Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LARA SHIRIKJIAN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1609193978
CMS profile
2786475
Location
TORRANCE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$137,308.00

148 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LARA SHIRIKJIAN

NPI 1609193978 · CMS profile ID 2786475

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

TORRANCE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609193978?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LARA SHIRIKJIAN, NPI 1609193978, CMS profile ID 2786475. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609193978?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LARA SHIRIKJIAN, NPI 1609193978, CMS profile ID 2786475. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609193978?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LARA SHIRIKJIAN, NPI 1609193978, CMS profile ID 2786475, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–148 of 148 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1609193978?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

148 matching records · $137,308.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 148 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–148 of 148.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Axsome Therapeutics, Inc. $276.6506/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297742 CMS
Janssen Scientific Affairs, LLC $21.6006/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078846053 CMS
Axsome Therapeutics, Inc. $32.9305/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297628 CMS
Janssen Scientific Affairs, LLC $6.7205/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078846071 CMS
Axsome Therapeutics, Inc. $170.1805/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297630 CMS
Axsome Therapeutics, Inc. $23.9005/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297632 CMS
Axsome Therapeutics, Inc. $125.0005/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297634 CMS
Axsome Therapeutics, Inc. $3,250.0005/22/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297636 CMS
Axsome Therapeutics, Inc. $7.5005/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297638 CMS
Axsome Therapeutics, Inc. $13.4004/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297620 CMS
Axsome Therapeutics, Inc. $123.4104/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297622 CMS
Axsome Therapeutics, Inc. $5.0004/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297624 CMS
Axsome Therapeutics, Inc. $2,250.0004/30/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297626 CMS
Axsome Therapeutics, Inc. $1,000.0004/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297618 CMS
Janssen Pharmaceuticals, Inc $4,800.0003/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943558 CMS
Axsome Therapeutics, Inc. $75.0003/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297588 CMS
Axsome Therapeutics, Inc. $10.1703/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297590 CMS
Axsome Therapeutics, Inc. $8,500.0003/09/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297592 CMS
Axsome Therapeutics, Inc. $35.0003/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297594 CMS
Axsome Therapeutics, Inc. $35.0003/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297596 CMS
Axsome Therapeutics, Inc. $78.2903/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297598 CMS
Axsome Therapeutics, Inc. $140.0003/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297600 CMS
Axsome Therapeutics, Inc. $35.0003/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297602 CMS
Axsome Therapeutics, Inc. $21.1403/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297604 CMS
Axsome Therapeutics, Inc. $25.0203/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297606 CMS
Axsome Therapeutics, Inc. $253.4903/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297608 CMS
Axsome Therapeutics, Inc. $11.3903/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297610 CMS
Axsome Therapeutics, Inc. $35.0003/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297612 CMS
Axsome Therapeutics, Inc. $21.3003/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297614 CMS
Axsome Therapeutics, Inc. $318.1903/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297616 CMS
Janssen Pharmaceuticals, Inc $19.2002/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943132 CMS
Janssen Pharmaceuticals, Inc $54.5102/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943248 CMS
Janssen Pharmaceuticals, Inc $18.1802/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943392 CMS
Janssen Pharmaceuticals, Inc $36.3702/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943480 CMS
Janssen Pharmaceuticals, Inc $106.3002/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943514 CMS
Janssen Pharmaceuticals, Inc $13.5202/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943142 CMS
Janssen Pharmaceuticals, Inc $16.2202/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943190 CMS
Janssen Pharmaceuticals, Inc $11.2702/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943196 CMS
Janssen Pharmaceuticals, Inc $15.0002/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943298 CMS
Janssen Pharmaceuticals, Inc $94.0002/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943362 CMS
Janssen Pharmaceuticals, Inc $66.4002/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943436 CMS
Janssen Pharmaceuticals, Inc $29.3702/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943458 CMS
Janssen Pharmaceuticals, Inc $386.3202/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943590 CMS
Janssen Pharmaceuticals, Inc $347.3602/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943674 CMS
Janssen Pharmaceuticals, Inc $33.0602/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943690 CMS
Janssen Pharmaceuticals, Inc $124.8002/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1077943734 CMS
Axsome Therapeutics, Inc. $1,000.0002/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297642 CMS
Axsome Therapeutics, Inc. $1,000.0002/14/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148297640 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,370.70 13
PY2020 $7,665.00 7
PY2021 $22,557.64 36
PY2022 $37,345.11 56
PY2023 $38,330.66 64
PY2024 $137,308.00 148
PY2025 $311,230.94 354

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,900.00 1
PY2025 Principal investigator $2,553,443.17 319
PY2024 Principal investigator $2,197,606.02 209
PY2023 Recipient $1,034.25 14
PY2023 Principal investigator $2,225,578.94 342
PY2022 Principal investigator $362,905.63 75
PY2021 Principal investigator $827,522.86 139
PY2020 Principal investigator $2,065,027.22 147
PY2019 Recipient $1,510.20 7
PY2019 Principal investigator $1,833,461.30 117

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

320 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 12/11/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049201
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 12/11/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049203
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,500.00 12/11/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049205
Principal investigator 1 ABBVIE INC. $31,807.02 12/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RES
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202529938
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 12/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242368485
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242368487
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242368489
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242368491
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242368493
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242368495
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 12/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242368497
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $101.00 12/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242368499
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737332
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737334
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737336
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737338
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737340
Principal investigator 1 Boehringer Ingelheim International GmbH $1,140.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737342
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737344
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737346
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737348
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737350
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737352
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737354
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737356
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737358
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737360
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737362
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737364
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737366
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737368
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737370
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737372
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737374
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737376
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737378
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737380
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737382
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737384
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737386
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737388
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737390
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737392
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737394
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737396
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737398
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737400
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737402
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,200.00 11/24/2025 Non-covered Recipient Entity
Collaborative Neuroscience Network, Llc
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder No dispute reported 06/30/2026 1235997934
Principal investigator 1 ABBVIE INC. $38,433.19 11/17/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RES
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202524483
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $562.93 11/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049146
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $168.88 11/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049148
Principal investigator 1 ABBVIE INC. $1,250.00 10/21/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RES
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202517703
Principal investigator 1 ABBVIE INC. $1,725.00 10/20/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RES
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202517455
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737294
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737296
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737298
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737300
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737302
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737304
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737306
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737308
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737310
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737312
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737314
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737316
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737318
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737320
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737322
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737324
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737326
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737328
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737330
Recipient ABBVIE INC. $3,900.00 09/26/2025 Covered Recipient Physician Major Depressive Disorder No dispute reported 06/30/2026 1202401337
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,626.81 09/24/2025 Non-covered Recipient Entity
Collaborative Neuroscience Network, Llc
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder No dispute reported 06/30/2026 1235997932
Principal investigator 1 ABBVIE INC. $14,472.90 09/19/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RES
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202511698
Principal investigator 1 ABBVIE INC. $500.00 09/12/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RES
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202510888
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,591.35 09/12/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049142
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $13,260.00 09/12/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049144
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 09/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242358586
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 09/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242358588
Principal investigator 1 ABBVIE INC. $10,545.00 09/03/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RES
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202508422
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $670.70 08/26/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049138
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,551.00 08/26/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049140
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 08/22/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737272
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 08/22/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737274
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 08/22/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737276
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737278
Principal investigator 1 Boehringer Ingelheim International GmbH $1,212.00 08/22/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737280
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737282
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737284
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737286
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737288
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737290
Principal investigator 1 Boehringer Ingelheim International GmbH $325.00 08/22/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737292
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,200.00 08/20/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242357648
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,514.00 08/20/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242357650
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,529.00 08/20/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242357656
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,640.25 08/14/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049132
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,200.00 08/14/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049134
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,560.00 08/14/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049136
Principal investigator 1 ABBVIE INC. $737.50 08/08/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202504149
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,738.10 08/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049126
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,500.00 08/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049128
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,950.00 08/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049130
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,516.20 07/31/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049124
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $26,001.79 07/30/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049195
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 07/28/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737262
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 07/28/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737264
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 07/28/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737266
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 07/28/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737268
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 07/28/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737270
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,996.74 07/28/2025 Non-covered Recipient Entity
Collaborative Neuroscience Network, Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder No dispute reported 06/30/2026 1235997930
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,750.00 07/28/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242355504
Principal investigator 1 ABBVIE INC. $3,215.60 07/24/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202499724
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,744.25 07/22/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049116
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,880.07 07/22/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049118
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $104.00 07/22/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049120
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $176.00 07/22/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049122
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,150.00 07/22/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049199
Principal investigator 1 ABBVIE INC. $420.83 07/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202498952
Principal investigator 1 ABBVIE INC. $9,458.00 07/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202498954
Principal investigator 1 ABBVIE INC. $21,186.34 07/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202498956
Principal investigator 1 ABBVIE INC. $208,754.66 07/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202498958
Principal investigator 1 ABBVIE INC. $12,189.00 07/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202498960
Principal investigator 1 ABBVIE INC. $1,275.00 07/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1202498962
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $112,210.40 07/18/2025 Non-covered Recipient Entity
Collaborative Neuroscience Network, Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder No dispute reported 06/30/2026 1235997936
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,000.00 07/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242353791
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,609.75 07/17/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049114
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,747.05 07/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049112
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $703.95 07/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049106
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $455.00 07/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049108
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $215.00 07/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049110
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,000.00 07/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049189
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 07/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049191
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 07/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049193
Principal investigator 1 ABBVIE INC. $1,656.24 07/01/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202493867
Principal investigator 1 ABBVIE INC. $4,208.29 07/01/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202493869
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737234
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737236
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737238
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737240
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737242
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737244
Principal investigator 1 Boehringer Ingelheim International GmbH $679.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737246
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737248
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737250
Principal investigator 1 Boehringer Ingelheim International GmbH $2,985.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737252
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737254
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737256
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737258
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/25/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737260
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,017.30 06/24/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049102
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,351.00 06/24/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049104
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,406.10 06/19/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049100
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,154.35 06/12/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049098
Principal investigator 1 ABBVIE INC. $11,909.78 06/11/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202490977
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,950.70 06/05/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049096
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,950.70 05/28/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049092
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $97,500.00 05/28/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049094
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,465.00 05/22/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049086
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20,494.35 05/22/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049088
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,351.00 05/22/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049090
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $277,500.00 05/16/2025 Non-covered Recipient Entity
Cenexel Cns - Torrance
An 8-week Open-label, Multicenter Randomized Study of Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment to Assess the Safety, Tolerability, and Efficacy in Participants with DSM-5 Schizophrenia No dispute reported 06/30/2026 1235998290
Principal investigator 1 Boehringer Ingelheim International GmbH $7,500.00 05/14/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737232
Principal investigator 1 ABBVIE INC. $1,200.00 04/28/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202479795
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,557.75 04/28/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049243
Principal investigator 1 ABBVIE INC. $29,318.90 04/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202478178
Principal investigator 1 ABBVIE INC. $3,517.31 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202474526
Principal investigator 1 ABBVIE INC. $22,111.67 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202474531
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339343
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339345
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339347
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339349
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339351
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339353
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,834.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339355
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,597.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339391
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $108.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339393
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $45.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339395
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $89.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339397
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339399
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339401
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339403
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339442
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339444
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339446
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,834.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339448
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,597.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339450
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $45.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339452
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,597.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339814
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 04/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242339816
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $78,662.85 03/26/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049241
Principal investigator 1 Boehringer Ingelheim International GmbH $264.55 03/24/2025 Non-covered Recipient Entity
Cenexel CNS-Torrance
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220737404
Principal investigator 1 ABBVIE INC. $39,828.05 03/19/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464847
Principal investigator 1 ABBVIE INC. $24,495.11 03/19/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464852
Principal investigator 1 ABBVIE INC. $28,687.05 03/19/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464864
Principal investigator 1 ABBVIE INC. $30,996.50 03/19/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464868
Principal investigator 1 Sumitomo Pharma America, Inc. $22,484.80 03/19/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176630561
Principal investigator 1 Sumitomo Pharma America, Inc. $540.80 03/19/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176630593
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,351.00 03/19/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049239
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334810
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334812
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334814
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334848
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334850
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334852
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334854
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334856
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334890
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334892
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334894
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334896
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,412.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334898
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334950
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,036.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334952
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334954
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334956
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242334958
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335010
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,874.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335012
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335014
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335016
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335018
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335020
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335022
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335078
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,303.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335080
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335082
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335084
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335086
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335088
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335090
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335130
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335132
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,834.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335134
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335136
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $101.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335138
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,412.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335140
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335142
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,036.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335194
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335196
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335198
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335200
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335202
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,874.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335204
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335206
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335240
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335242
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335244
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335246
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335248
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,303.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335250
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $101.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335252
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $45.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335402
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,412.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335404
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335406
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,036.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335408
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335410
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335412
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335444
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335446
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,874.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335448
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335450
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335452
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335454
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335456
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335474
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335476
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335478
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335480
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335482
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335484
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335486
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,303.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335488
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335490
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335528
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335530
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,096.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335532
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335534
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $101.00 03/10/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242335536
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,556.30 03/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049235
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,351.00 03/04/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049237
Principal investigator 1 Sumitomo Pharma America, Inc. $28,498.00 03/03/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176629985
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $11,767.65 02/25/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049233
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,131.40 02/20/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049261
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,135.22 02/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049223
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $122.50 02/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049225
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $977.32 02/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049227
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,500.53 02/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049229
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,650.16 02/18/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049231
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $25.48 02/11/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049209
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,722.90 02/11/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049221
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332094
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332196
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332198
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332200
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332202
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332204
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332206
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332210
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332296
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332298
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332300
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332302
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332304
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,834.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332306
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,828.00 02/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
ITI-007-452 No dispute reported 06/30/2026 1242332308
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $124,567.94 01/30/2025 Non-covered Recipient Entity
Collaborative Neuroscience Network
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1235997944
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,083.20 01/29/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049219
Principal investigator 1 Sumitomo Pharma America, Inc. $750.00 01/28/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176624743
Principal investigator 1 Sumitomo Pharma America, Inc. $2,000.00 01/28/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176624751
Principal investigator 1 Sumitomo Pharma America, Inc. $3,506.00 01/28/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176624764
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,544.45 01/21/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049217
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,235.30 01/17/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049215
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $102,867.18 01/15/2025 Non-covered Recipient Entity
Collaborative Neuroscience Network
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia No dispute reported 06/30/2026 1235997940
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,538.05 01/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049211
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,057.80 01/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia No dispute reported 06/30/2026 1244049213
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $17,494.58 01/07/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244049259
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $352,857.80 01/06/2025 Non-covered Recipient Entity
Collaborative Neuroscience Network
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) No dispute reported 06/30/2026 1235997942